TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01596985

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystectomy
Description: Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C).
Study: NCT02750592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
Description: Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
Study: NCT03512314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa
Description: Open label, 26 weeks on Tadekinig alfa treatment.
Study: NCT04611750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036
Description: AD036 will be given for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for 14 days
Study: NCT00671307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhu-pGelsolin
Description: IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
Study: NCT01510782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 655064
Description: intravenous infusion of escalating doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 655064
Description: subcutaneous injection of escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: intravenous infusion of escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection of escalating doses
Study: NCT03940131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFOX6 regimen will be repeated at 2-week intervals. FOLFIRI regimen consists of 2-hour infusion of irinotecan (180 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFIRI regimen will be repeated at 2-week intervals.
Study: NCT00671307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhu-pGelsolin
Description: IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhu-pGelsolin
Description: IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle control given as IV infusion over 1 hour
Study: NCT03794388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Application of capsaicin patches at 8% on painful area

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Taking Pregabalin tablets
Study: NCT03626376

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily
Description: Treatment used in standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
Description: Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
Study: NCT01629368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Multiple doses of carbamazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Single dose of RO4917523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Single dose of RO4917523
Study: NCT00322946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN4delta30-4995
Description: Live attenuated rDEN4delta30-4995 vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN4delta30-4995
Study: NCT04139720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-book
Description: sexual harassment prevention via education e-book
Study: NCT03812198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 32731
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 32731
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
Study: NCT02084472

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baby oil
Description: patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: petroleum jelly
Description: patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine:petroleum jelly 2:1
Description: patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
Study: NCT04040166

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/MRI of carotid arteries with 68Ga DOTATATE
Description: PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
Study: NCT00715039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam
Description: 1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: 20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
Study: NCT01246921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone proprionate 0.05% cream
Description: Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
Study: NCT01181336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (FLU-v)
Description: Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
Study: NCT01009502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium stibogluconate
Description: Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
Study: NCT03254498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff
Description: It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cap assisted colonoscopy (CAC)
Description: cap assisted colonoscopy (CAC)
Study: NCT03655223

Intervention type: DIAGNOSTIC_TEST
Intervention: Confirmatory Testing
Description: If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
Study: NCT02630368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and JX-594 dose escalation
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and JX-594
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and JX-594
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab and JX-594 and Cyclophosphamide
Description: Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab and JX-594 and Cyclophosphamide
Description: Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections .
Study: NCT04034940

Intervention type: OTHER
Group type: OTHER
Intervention: Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients
Description: Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
Study: NCT00990912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
Study: NCT03449433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Administered SC
Study: NCT00378248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined psychotherapy
Description: 18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
Study: NCT04546724

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA1553
Description: Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
Study: NCT00562939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccines + CPG 7909
Description: Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal vaccines
Description: Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
Study: NCT00520663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-SB649868
Description: SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
Study: NCT01382706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study: NCT03574350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KS in Kangaroo Position
Description: KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KS in incubator
Description: The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
Study: NCT01382706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01181336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (FLU-v)
Description: Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (FLU-v)
Description: Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (FLU-v)
Description: Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FLU-v Control
Description: Adjuvant only or water for injection only Administration: a single subcutaneous injection
Study: NCT01289028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT01987609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT04020393

Intervention type: PROCEDURE
Intervention: SPGB
Description: SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
Study: NCT04094727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presumptive treatment with Artemether-lumefantrine (AL)
Description: All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced vector control
Description: The mop up indoor residual spraying (IRS) campaign will be targeted to farms and cattle posts/kraals in intervention areas in December 2019 to fill gaps from the routine spray campaign (September to November 2019) and utilize the same insecticides and protocols as the national campaign. The team will spray each unsprayed structure with the recommended solution of dichloro-diphenyl-trichloroethane (DDT) for traditional structures and/or Actellic for modern structures, tarps and tents.~Alternative vector control interventions, including LLINs (long-lasting insecticide treated bed nets), sprayed tents/tarps and topical repellents will be distributed to eligible HRPs between November and January 2020 during one round.
Study: NCT01872286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKE-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKE-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillcam SB2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillcam SB2
Study: NCT02871544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BNP and NGAL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BNP and NGAL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BNP and NGAL

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: BNP and NGAL
Study: NCT00378248

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient individual psychotherapy
Description: Eclectic individual psychotherapy in private practice
Study: NCT02162212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Shoulder Movement Program
Description: A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADA Guideline Instructed
Description: The ADA guideline instructions are to include: blood sugar control (goal is A1c \< 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is \<130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.